Literature DB >> 33793318

Reply to K. Ando et al.

Joseph A Sparano1, Michael R Crager1, Gong Tang1, Robert J Gray1, Salomon M Stemmer1, Steven Shak1.   

Abstract

Entities:  

Year:  2021        PMID： 33793318      PMCID： PMC8260921          DOI： 10.1200/JCO.21.00424

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   50.717


× No keyword cloud information.
  9 in total

1.  Amenorrhea from breast cancer therapy--not a matter of dose.

Authors:  Sandra M Swain; Jong-Hyeon Jeong; Norman Wolmark
Journal:  N Engl J Med       Date:  2010-12-02       Impact factor: 91.245

2.  What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer?

Authors:  Kenju Ando; Akihiko Shimomura; Kenichi Yoshimura; Yukino Kawamura; Chikako Shimizu
Journal:  J Clin Oncol       Date:  2021-04-01       Impact factor: 44.544

3.  Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathy S Albain; Thomas J Saphner; Sunil S Badve; Lynne I Wagner; Virginia G Kaklamani; Maccon M Keane; Henry L Gomez; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Deborah L Toppmeyer; Adam M Brufsky; Matthew P Goetz; Jeffrey L Berenberg; Catalin Mahalcioiu; Christine Desbiens; Daniel F Hayes; Elizabeth C Dees; Charles E Geyer; John A Olson; William C Wood; Tracy Lively; Soonmyung Paik; Matthew J Ellis; Jeffrey Abrams; George W Sledge
Journal:  JAMA Oncol       Date:  2020-03-01       Impact factor: 31.777

Review 4.  Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer.

Authors:  Janice M Walshe; Neelima Denduluri; Sandra M Swain
Journal:  J Clin Oncol       Date:  2006-11-27       Impact factor: 44.544

5.  Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-09-19       Impact factor: 79.321

6.  Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter M Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

7.  Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.

Authors:  Gong Tang; Jack Cuzick; Joseph P Costantino; Mitch Dowsett; John F Forbes; Michael Crager; Eleftherios P Mamounas; Steven Shak; Norman Wolmark
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

8.  Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.

Authors:  Olivia Pagani; Prudence A Francis; Gini F Fleming; Barbara A Walley; Giuseppe Viale; Marco Colleoni; István Láng; Henry L Gómez; Carlo Tondini; Graziella Pinotti; Angelo Di Leo; Alan S Coates; Aron Goldhirsch; Richard D Gelber; Meredith M Regan
Journal:  J Clin Oncol       Date:  2019-10-16       Impact factor: 44.544

9.  Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer.

Authors:  Joseph A Sparano; Michael R Crager; Gong Tang; Robert J Gray; Salomon M Stemmer; Steven Shak
Journal:  J Clin Oncol       Date:  2020-12-11       Impact factor: 50.717
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.